HomeCompareMAXQF vs ABBV

MAXQF vs ABBV: Dividend Comparison 2026

MAXQF yields 438.79% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAXQF wins by $22708.76M in total portfolio value
10 years
MAXQF
MAXQF
● Live price
438.79%
Share price
$0.46
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22708.86M
Annual income
$15,679,518,541.24
Full MAXQF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MAXQF vs ABBV

📍 MAXQF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMAXQFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MAXQF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MAXQF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MAXQF
Annual income on $10K today (after 15% tax)
$37,297.06/yr
After 10yr DRIP, annual income (after tax)
$13,327,590,760.05/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MAXQF beats the other by $13,327,569,704.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MAXQF + ABBV for your $10,000?

MAXQF: 50%ABBV: 50%
100% ABBV50/50100% MAXQF
Portfolio after 10yr
$11354.48M
Annual income
$7,839,771,656.50/yr
Blended yield
69.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MAXQF
No analyst data
Altman Z
2.8
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MAXQF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMAXQFABBV
Forward yield438.79%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$22708.86M$102.3K
Annual income after 10y$15,679,518,541.24$24,771.77
Total dividends collected$22077.80M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MAXQF vs ABBV ($10,000, DRIP)

YearMAXQF PortfolioMAXQF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$54,579$43,878.89$11,550$430.00+$43.0KMAXQF
2$282,218$223,818.83$13,472$627.96+$268.7KMAXQF
3$1,383,590$1,081,616.28$15,906$926.08+$1.37MMAXQF
4$6,436,217$4,955,776.33$19,071$1,382.55+$6.42MMAXQF
5$28,431,989$21,545,236.75$23,302$2,095.81+$28.41MMAXQF
6$119,371,836$88,949,607.26$29,150$3,237.93+$119.34MMAXQF
7$476,751,535$349,023,670.94$37,536$5,121.41+$476.71MMAXQF
8$1,812,874,891$1,302,750,748.56$50,079$8,338.38+$1812.82MMAXQF
9$6,569,480,795$4,629,704,660.99$69,753$14,065.80+$6569.41MMAXQF
10$22,708,862,992$15,679,518,541.24$102,337$24,771.77+$22708.76MMAXQF

MAXQF vs ABBV: Complete Analysis 2026

MAXQFStock

Maritime Launch Services Inc. operates as a commercial space company in Nova Scotia. It is developing Spaceport Nova Scotia, a launch site that provides satellite delivery services, which enables clients in the commercial space transportation industry to place their satellites into low-earth orbit. The company is headquartered in Halifax, Canada.

Full MAXQF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MAXQF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MAXQF vs SCHDMAXQF vs JEPIMAXQF vs OMAXQF vs KOMAXQF vs MAINMAXQF vs JNJMAXQF vs MRKMAXQF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.